×
About 703 results

ALLMedicine™ Becker Muscular Dystrophy Center

Research & Reviews  254 results

Dilated cardiomyopathy as the initial presentation of Becker muscular dystrophy: a syst...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097097
Orphanet Journal of Rare Diseases; Del Rio-Pertuz G, Morataya C et. al.

May 14th, 2022 - There are scarce publications regarding the presentation and outcome of Becker muscular dystrophy in adulthood when idiopathic dilated cardiomyopathy is the initial disease manifestation. We performed a systematic review using Medline, Embase, Coc...

2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in ...
https://doi.org/10.1016/j.hrthm.2022.04.022
Heart Rhythm; Groh WJ, Bhakta D et. al.

May 3rd, 2022 - This international multidisciplinary document is intended to guide electrophysiologists, cardiologists, other clinicians, and health care professionals in caring for patients with arrhythmic complications of neuromuscular disorders (NMDs). The doc...

Defining Endpoints in Becker Muscular Dystrophy
https://clinicaltrials.gov/ct2/show/NCT05257473

Apr 29th, 2022 - Becker Muscular Dystrophy (BMD) is most frequently due to in-frame mutations in the dystrophin gene that are associated with reduced levels of frequently shortened dystrophin, though other mutations may be related to the Becker phenotype. There is...

Body composition and myokines in a cohort of patients with Becker muscular dystrophy.
https://doi.org/10.1002/mus.27565
Muscle & Nerve; Barp A, Carraro E et. al.

Apr 28th, 2022 - Becker muscular dystrophy (BMD) is an X-linked disease leading to muscle wasting and weakness. The decrease in lean body mass (LBM) in Duchenne muscular dystrophy, has shown correlation with loss of muscle function and bone density (BD). Myokines ...

Health Care Use of Cardiac Specialty Care in Children With Muscular Dystrophy in the Un...
https://doi.org/10.1161/JAHA.121.024722
Journal of the American Heart Association; Mejia EJ, Lin KY et. al.

Apr 13th, 2022 - Background Duchenne and Becker muscular dystrophy are progressive disorders associated with cardiac mortality. Guidelines recommend routine surveillance; we assess cardiac resource use and identify gaps in care delivery. Methods and Results Male p...

see more →

Guidelines  1 results

2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in ...
https://doi.org/10.1016/j.hrthm.2022.04.022
Heart Rhythm; Groh WJ, Bhakta D et. al.

May 3rd, 2022 - This international multidisciplinary document is intended to guide electrophysiologists, cardiologists, other clinicians, and health care professionals in caring for patients with arrhythmic complications of neuromuscular disorders (NMDs). The doc...

see more →

Clinicaltrials.gov  15 results

Defining Endpoints in Becker Muscular Dystrophy
https://clinicaltrials.gov/ct2/show/NCT05257473

Apr 29th, 2022 - Becker Muscular Dystrophy (BMD) is most frequently due to in-frame mutations in the dystrophin gene that are associated with reduced levels of frequently shortened dystrophin, though other mutations may be related to the Becker phenotype. There is...

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy
https://clinicaltrials.gov/ct2/show/NCT05291091

Mar 24th, 2022 - This study is a double-blind, randomized, placebo-controlled design to investigate the effect of EDG-5506 on the safety, pharmacokinetics, biomarkers and functional measures. Approximately 36 adults and 18 adolescents with Becker muscular dystroph...

Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
https://clinicaltrials.gov/ct2/show/NCT04386304

Mar 23rd, 2022 - The safety and tolerability of three escalating doses of (+)-epicatechin will be assessed and early effectiveness measured by changes in plasma biomarkers, tissue biomarkers from muscle biopsies, cardiac imaging, and on clinical function assessmen...

Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)
https://clinicaltrials.gov/ct2/show/NCT01856868

Dec 22nd, 2021 - This is a proof-of-concept phase 1/2a pilot and endpoint development study that is designed to provide initial evidence of biological activity of (-)-epicatechin. Primary endpoints include initial assessment of tissue-specific evidence of efficacy...

Swiss Registry for Neuromuscular Disorders
https://clinicaltrials.gov/ct2/show/NCT05102916

Nov 11th, 2021 - Background: The 'Swiss registry for neuromuscular disorders' (Swiss-Reg-NMD) collects medical information from people with neuromuscular disorders. It is led by specialized physicians from all over Switzerland and located at the Institute of Socia...

see more →

News  8 results

HeartMate 3 OK'd for Destination Tx; Pradaxa Flops in ESUS; Heater-Cooler Infection
https://www.medpagetoday.com/cardiology/prevention/75852

Oct 22nd, 2018 - The HeartMate 3 left ventricular assist device (LVAD) gained an indication for destination therapy. (Star Tribune) Dabigatran (Pradaxa) was no better than aspirin for prevention of recurrent stroke among patients with an embolic stroke of undeterm...

Clinical Outcome Assessments (COA) Qualification Program Submissions
http://www.fda.gov/drugs/clinical-outcome-assessment-coa-qualification-program/clinical-outcome-assessments-coa-qualification-program-submissions

The tables below list information about submissions to the FDA Clinical Outcome Assessments (COA) Qualification Program for which final COA qualification determinations have not yet been made. The tables include legacy projects (those submitted pr...

Clinical Outcome Assessments (COA) Qualification Submissions
http://www.fda.gov/drugs/clinical-outcome-assessment-coa-qualification-program/clinical-outcome-assessments-coa-qualification-submissions

The tables below list information about submissions to the FDA Clinical Outcome Assessments (COA) Qualification Program for which final COA qualification determinations have not yet been made. The tables include legacy projects (those submitted pr...

Early ACE Inhibitors Can Slow Myocardial Fibrosis Progression in Muscular-Dystrophy Patients
https://www.medscape.com/viewarticle/873078

Dec 8th, 2016 - SÃO PAULO, BRAZIL — Early administration of ACE inhibitors can slow progression of myocardial fibrosis (MF) in youth males with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), according to results of a clinical trial[1]. Dr C...

CHMP Says Renew Conditional Approval of Ataluren for DMD
https://www.medscape.com/viewarticle/871798

Nov 11th, 2016 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended renewal of conditional marketing authorization for ataluren (Translarna, PTC Therapeutics) for treatment of Duchenne muscular dystrophy (DMD)...

see more →

Patient Education  3 results see all →